X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
niraparib (67) 67
oncology (34) 34
ovarian cancer (34) 34
index medicus (31) 31
olaparib (25) 25
rucaparib (20) 20
parp inhibitors (19) 19
poly polymerase (17) 17
cancer (16) 16
chemotherapy (16) 16
parp inhibitor (16) 16
pharmacology & pharmacy (15) 15
homologous recombination (11) 11
humans (11) 11
maintenance therapy (10) 10
platinum (10) 10
breast cancer (9) 9
inhibitors (9) 9
medicine & public health (9) 9
monosaccharides (8) 8
open-label (8) 8
sugars (8) 8
bevacizumab (7) 7
dna repair (7) 7
double-blind (7) 7
female (7) 7
mutation (7) 7
olaparib maintenance therapy (7) 7
pharmacokinetics (7) 7
review (7) 7
ribose (7) 7
tumors (7) 7
veliparib (7) 7
analysis (6) 6
carcinoma (6) 6
mk-4827 (6) 6
obstetrics & gynecology (6) 6
ovarian neoplasms - drug therapy (6) 6
patients (6) 6
polymerase (6) 6
talazoparib (6) 6
therapy (6) 6
adp (5) 5
antitumor-activity (5) 5
brca (5) 5
breast-cancer (5) 5
cancer therapies (5) 5
endocrine system diseases (5) 5
inhibitor (5) 5
mutations (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
parp (5) 5
pharmacology/toxicology (5) 5
repair (5) 5
toxicity (5) 5
cancer research (4) 4
cell line, tumor (4) 4
dna damage (4) 4
epithelial ovarian cancer (4) 4
fallopian-tube (4) 4
grade serous ovarian (4) 4
homologous recombination deficiency (4) 4
inhibitor niraparib (4) 4
negative breast-cancer (4) 4
ovarian carcinoma (4) 4
poly (4) 4
poly polymerase inhibitors (4) 4
primary peritoneal (4) 4
recurrent (4) 4
resistance (4) 4
survival (4) 4
thrombocytopenia (4) 4
53bp1 (3) 3
ams (3) 3
anemia (3) 3
article (3) 3
bioavailability (3) 3
biotechnology (3) 3
brca mutation carriers (3) 3
brca mutations (3) 3
cells (3) 3
clinical trials (3) 3
combination (3) 3
confidence intervals (3) 3
deoxyribonucleic acid--dna (3) 3
drug approval (3) 3
durvalumab (3) 3
fallopian tube (3) 3
female genital diseases and pregnancy complications (3) 3
liquid chromatography (3) 3
mass spectrometry (3) 3
medical colleges (3) 3
medical research (3) 3
metabolites (3) 3
multicenter (3) 3
ovarian neoplasms - genetics (3) 3
pegylated liposomal doxorubicin (3) 3
peritoneum (3) 3
pharmacology (3) 3
platinum-sensitive ovarian (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 36, pp. 3999 - 4002
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 01/2018, Volume 81, Issue 1, p. 39
INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance... 
LC-MS/MS | 14C-microtracer | AMS | Niraparib | Bioavailability | Pharmacokinetics
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 08/2018, Volume 18, Issue 8, pp. 727 - 733
Introduction: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved... 
BRCA | Niraparib | ovarian cancer | homologous recombination deficiency | PARP inhibitor | GERMLINE | MANAGEMENT | SAFETY | INHIBITOR NIRAPARIB | ANTITUMOR-ACTIVITY | MAINTENANCE THERAPY | ONCOLOGY | RECURRENT | BRCA1/2 MUTATION | PARP INHIBITORS | CARCINOMA | Index Medicus
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 02/2019, Volume 152, Issue 2, pp. 265 - 269
Niraparib is a poly (ADP-ribose) polymerase inhibitor (PARP) approved for use in maintenance therapy for ovarian cancer that is associated with the... 
Thrombocytopenia | Niraparib | Creatinine clearance | Drug interactions | PARP inhibitors | ONCOLOGY | INHIBITOR | OBSTETRICS & GYNECOLOGY | Index Medicus
Journal Article
by Yang, HQ and Zeng, QL and He, Z and Wu, D and Li, H
NEW JOURNAL OF CHEMISTRY, ISSN 1144-0546, 05/2019, Volume 43, Issue 17, pp. 6702 - 6711
The binding interaction of niraparib (MK-4827), a poly(ADP-ribose) polymerase inhibitor, with calf thymus deoxyribonucleic acid (ctDNA) has been explored by... 
CTDNA | THERAPY | PARAMETERIZATION | HUMAN SERUM-ALBUMIN | DOCKING | SITES | MECHANISMS | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY | NIRAPARIB
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2019, Volume 84, Issue 4, pp. 791 - 798
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 98, pp. 37080 - 37096
Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of both mutant (mut)... 
Niraparib | Brain exposure | Tumor exposure | BRCAwt tumor | Intracranial tumor
Journal Article
Taiwanese Journal of Obstetrics & Gynecology, ISSN 1028-4559, 10/2017, Volume 56, Issue 5, pp. 713 - 714
Journal Article
INVESTIGATIONAL NEW DRUGS, ISSN 0167-6997, 12/2017, Volume 35, Issue 6, pp. 751 - 765
Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16... 
Mass balance | TRA | Radiolabelled | Metabolites | ONCOLOGY | ADME | Niraparib | PHARMACOLOGY & PHARMACY
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1366 - 1376
Abstract For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of antiangiogenic... 
Phase III | Niraparib | Olaparib | Rucaparib | PARP inhibitor | Ovarian cancer | GRADE SEROUS OVARIAN | ovarian cancer | phase III | FALLOPIAN-TUBE | ANTITUMOR-ACTIVITY | OLAPARIB MAINTENANCE THERAPY | BREAST-CANCER | DOSE-ESCALATION | PARR inhibitor | rucaparib | ONCOLOGY | olaparib | niraparib | DOUBLE-BLIND | EPITHELIAL OVARIAN | PRIMARY PERITONEAL | BRCA2 MUTATION
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 04/2019, Volume 153, Issue 1, pp. 127 - 134
Objective. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in homologous recombination- (HR-) deficient ovarian cancer and are... 
CELLS | PROFICIENT | MULTICENTER | 53BP1 | PARP inhibitors | DNA damage | OPEN-LABEL | Ovarian cancer | NIRAPARIB | REPAIR | POLYMERASE INHIBITORS | RESISTANCE | MUTATIONS | HR-deficiency | CARCINOMA
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 02/2019, Volume 73, pp. 1 - 9
Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have... 
Niraparib | Olaparib | Rucaparib | PARP inhibitors | Ovarian cancer | BRCA2 MUTATIONS | MUTATION CARRIERS | OPEN-LABEL | MAINTENANCE THERAPY | NEGATIVE BREAST-CANCER | ONCOLOGY | DOUBLE-BLIND | HOMOLOGOUS RECOMBINATION | PHASE-I | CARCINOMA | Medical colleges | Drug approval | Sugars | Monosaccharides
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 08/2018, Volume 27, Issue 15, pp. 1714 - 1717
Journal Article
Arzneimitteltherapie, ISSN 0723-6913, 10/2018, Volume 36, Issue 10, pp. 340 - 345
Journal Article
Molecules, ISSN 1420-3049, 05/2019, Volume 24, Issue 10, p. 1901
A series of benzimidazole carboxamide derivatives have been synthesized and characterized by H-1-NMR, C-13-NMR and HRMS. PARP inhibition assays and cellular... 
Poly(ADP-ribose) polymerase | Benzimidazole carboxamide | PARP enzyme inhibition | benzimidazole carboxamide | DESIGN | poly(ADP-ribose) polymerase | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, MULTIDISCIPLINARY | NIRAPARIB
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 06/2018, Volume 19, Issue 6, pp. 525 - 533
The irreversible ERBB1/2/4 inhibitor neratinib has been shown to rapidly down-regulate the expression of ERBB1/2/4 as well as the levels of c-MET, PDGFRα and... 
neratinib | receptor tyrosine kinase | Autophagy | niraparib | POLY(ADP-RIBOSE) POLYMERASE | TUMORS | BREAST-CANCER | BECLIN 1 EXPRESSION | ONCOLOGY | IN-VIVO | LINE | RESISTANCE | RECEPTORS | CARCINOMA
Journal Article
Drugs in Context, ISSN 1745-1981, 08/2018, Volume 7, pp. 212540 - 30
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching... 
Rucaparib | PARP inhibitor | Veliparib | Niraparib | Breast cancer | Olaparib | Talazoparib | BRCA1 | BRCA2 | rucaparib | niraparib | olaparib | breast cancer | veliparib | talazoparib
Journal Article
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, ISSN 1386-1425, 01/2019, Volume 206, pp. 126 - 134
The interactions between 2-{4-[(3 )-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide (niraparib) and human serum albumin (HSA) were investigated through... 
Fluorescence | Human serum albumin | Niraparib | Molecular dynamics simulation | Molecular docking | DRUG | ACID | X-RAY CRYSTALLOGRAPHY | MECHANISM | CONFORMATION | MASS-SPECTROMETRY | NANOPARTICLES | SPECTROSCOPY | BINDING | Molecular dynamics | Albumin | Thermodynamics | Analysis | Methods
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.